Moderna
MRNA
Market cap $15.2B

39.39 USD

-0.17

0.43%

At close Dec 20, 4:00 PM EST

After hours

39.64

+0.25

0.63%

1 day

-0.43%

5 days

-6.57%

1 month

6.63%

3 months

-40.04%

6 months

-70.69%

Year to date

-64.99%

1 year

-54.30%

5 years

98.64%

10 years

111.77%

About: Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Employees: 5,600

Healthcare Biological Products, Except Diagnostic Substances

Funds holding %

of 6,809 funds

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2.73% less ownership

Funds ownership: 69.74% [Q2] → 67.01% (-2.73%) [Q3]

18% less funds holding

Funds holding: 929 [Q2] → 765 (-164) [Q3]

21% less repeat investments, than reductions

Existing positions increased: 250 | Existing positions reduced: 316

36% less call options, than puts

Call options by funds: $926M | Put options by funds: $1.46B

46% less capital invested

Capital invested by funds: $31.8B [Q2] → $17.2B (-$14.6B) [Q3]

46% less funds holding in top 10

Funds holding in top 10: 13 [Q2] → 7 (-6) [Q3]

73% less first-time investments, than exits

New positions opened: 62 | Existing positions closed: 226

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$40

upside

Avg. target

$65

64%

upside

High target

$111

182%

upside

9 analyst ratings

4 positive

44%

2 neutral

22%

3 negative

33%

B of A Securities Tim Anderson 50% 1-year accuracy 3 / 6 met price target	4%upside $41	Underperform Reinstated	10 Dec 2024
JP Morgan Jessica Fye 50% 1-year accuracy 20 / 40 met price target	14%upside $45	Underweight Maintained	26 Nov 2024
Piper Sandler Edward Tenthoff 23% 1-year accuracy 10 / 43 met price target	75%upside $69	Overweight Reiterated	18 Nov 2024
HSBC Yifeng Liu 67% 1-year accuracy 2 / 3 met price target	47%upside $58	Buy Upgraded	18 Nov 2024
Wolfe Research Alexandria Hammond 33% 1-year accuracy 3 / 9 met price target	2%upside $40	Underperform Initiated	15 Nov 2024